Home » Newsletters » BioWorld Science

BioWorld Science

March 2, 2004

View Archived Issues

Nektar Therapeutics updates year-end 2003 progress

Good pharmacological profile and antitumor activity of topoisomerase I-active agent BMS-251873

Aromatase inhibitors may help increase adult height in boys with CDP

Lower risk for Hodgkin's lymphoma reported to be associated with aspirin use

Promising results found for an autologous melanoma cancer vaccine

Acetylcysteine improves cardiovascular morbidity in renal failure

MediciNova acquires KUR-1246

Pevion Biotech and AlgoNomics collaborate on rational vaccine development

Amarin Pharmaceuticals subsidiary sold to Valeant

Study shows more accurate compliance for Orth Evra than oral contraceptives

deCODE and Merck form drug development alliance

Enzo Biochem acquires OraGen

Novel proapoptotic IAP-binding agents identified at Princeton University

Paratek claims tetracyclines for use in infections, inflammation, cancer, etc.

Two series of inhibitors of alpha4 integrin-mediated cell adhesion reported by Celltech

Three series of antitumor epothilones described by GBF and Morphochem researchers

Novel STAT6 inhibitors for respiratory and allergic disorders claimed by Yamanouchi

Sanofi-Synthelabo scientists present new vasopressin receptor ligands

New VPAC2 agonists in early development at Bayer

BSP-201 dietary supplements for arthritis approved for sale in U.S.

CPMP hands down positive opinion for Levemir

Alvesco receives first approval in Australia

Menactra BLA accepted for filing

Norditropin Nordiflex approved in Japan

Completion of extended phase I trial for Islet Neogenesis Therapy

Recommended approval in Europe for TachoSil

Positive opinion in Europe for Abilify

Avian influenza A in Vietnamese patients

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 8, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 8, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ASH 2025: New blood cancer therapies trump chemo, older drugs
BioWorld
Targeted therapies and immunotherapies continue to show better results than chemotherapy in investigator-initiated and company-sponsored cancer trials, and newer...